Latest Biotech News

Roche is making a deeper play in obesity by extending its China deal streak with a $1.2B pact for an ALK7 RNA interference program from Rona Therapeutics, targeting a genetically validated driver...

Enodia Therapeutics and Pfizer struck a research collaboration and licensing agreement to discover and develop small-molecule Sec61 inhibitors. Enodia will run discovery, optimization, and...

Ohio State investigators reported early clinical signals from a phase I study using fresh, rapidly manufactured CAR T cells engineered to target three B-cell proteins and boosted with OX40. In...

Happy Health received FDA clearance for its cuffless wearable ring that continuously measures blood pressure without a cuff or external calibration. The clearance supports commercialization of a...

Verdiva Bio terminated one of its Phase 2 trials of a GLP-1 pill candidate, citing “market evolution,” according to the report. The decision highlights the ongoing volatility in obesity...

UCB dedicated its planned Rowen, Georgia biologics manufacturing campus, setting out a $2 billion investment. The site is described as UCB’s first U.S. manufacturing location and is intended to...

Researchers at Aarhus University demonstrated a prime-editing approach that corrects genetic defects in a patient’s own blood stem cells in a study focused on GATA2 deficiency. The report says the...

U.S. national surveillance data show clinical cases of Candida auris climbed from 2,882 in 2022 to 6,197 in 2024—more than doubling in two years—according to a CDC Morbidity and Mortality Weekly...

A two-year Japanese real-world study reports sustained high clearance rates across genital, scalp, and nail psoriasis for bimekizumab, a dual IL-17A/IL-17F inhibitor. The report describes...

The NIH is weighing changes to how grant review impact scores are disclosed to applicants, with a proposal to conceal numerical scores and replace them with broad tier buckets such as top 25%,...

Roche moved further into obesity by licensing an RNA interference program aimed at ALK7 from Rona Therapeutics, adding to a run of late-stage metabolic deals. The collaboration centers on...

Ohio State investigators reported early results for a newly engineered CAR T-cell approach targeting three B-cell proteins and incorporating OX40 co-stimulation. In a phase I setting for relapsed...

Enodia Therapeutics entered a research collaboration and licensing agreement with Pfizer to discover and develop small-molecule Sec61 inhibitors. Enodia will run discovery and optimization across...

Happy Health received FDA clearance for its cuffless wearable blood pressure ring designed to continuously measure blood pressure without a cuff or external calibration. The clearance supports the...

CDC surveillance data show clinical Candida auris cases more than doubled from 2022 to 2024, with the fungus now classified as an urgent antimicrobial resistance threat. The report links the...

A first-in-human phase I study reported that IMM60—a liposomal iNKT cell agonist—was well tolerated alone or with pembrolizumab in patients with advanced melanoma and non-small cell lung cancer....

Vanderbilt researchers built a reusable electronic health record pipeline that converts minute-by-minute ICU arterial blood pressure streams into research-ready longitudinal profiles. The approach...

A study analyzing 775 SFTS patients found that a six-biomarker panel and early biomarker trajectories can flag patients at high risk of fatal cardiogenic shock within the first week of...

Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million, linked to the FDA approval of GENGLYCOS (pariglasgene brebacarvovec-opnr), a one-time gene...

A new NIH rule proposal drew open criticism after it suggested concealing impact scores from grant applicants. Under the plan, reviews would still include written critiques and criterion factor...